Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

✍ Scribed by Nobuo Itoh; Hiroyuki Arai; Katsuya Urakami; Koichi Ishiguro; Hideto Ohno; Harald Hampel; Katharina Buerger; Jens Wiltfang; Markus Otto; Hans Kretzschmar; Hans-Juergen Moeller; Masaki Imagawa; Hideki Kohno; Kenji Nakashima; Shigeki Kuzuhara; Hidetada Sasaki; Kazutomo Imahori

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: English
• Weight: 189 KB
• Volume: 50
• Category: Article
• ISSN: 0364-5134
• DOI: 10.1002/ana.1054

✦ Synopsis

We surveyed a total of 570 cerebrospinal fluid (CSF) samples from a variety of diseases, including Alzheimer's disease (AD; n = 236), non-AD-demented and nondemented diseases (n = 239), and normal controls (n = 95) to quantitate levels of tau protein phosphorylated at serine 199 (CSF/phospho-tau199) by a recently established sandwich ELISA. The CSF/phospho-tau199 levels in the AD group were significantly elevated compared to those in all the other non-AD groups. Receiver operating characteristics curves showed that the diagnostic sensitivity and specificity for the AD group vs all the other non-AD groups using the CSF/phospho-tau199 were 85.2% and 85.0%, respectively. Furthermore, there was a significant positive correlation between CSF/phospho-tau199 and CSF/total-tau levels in the AD group. Elevated CSF/phospho-tau199 in the AD group was noted irrespective of age, gender, dementia severity, and number of apolipoprotein E4 alleles. Thus, we suggest that CSF/phospho-tau199 may be a novel and logical biomarker in supporting antemortem diagnosis of AD.